TolerogenixX revolutionises kidney transplantation
TolerogenixX expands Phase II immune-tolerance trial and closes EUR 12 million Series A financing
12-Jul-2023 -
TolerogenixX GmbH, a biopharmaceutical company developing personalized cellular therapies aimed at achieving sustained immune tolerance to combat organ rejection and autoimmune diseases, announced that in the TOL2- Phase IIb study in renal transplant patients TolerogenixX has received green light ...
cell therapies
immunosuppression
organ transplantation
+1